British Journal of Clinical Pharmacology

Introduction: Conventional substance-level disproportionality analysis may miss safety patterns specific to a dose form, route, or intended site. More granular analyses are hindered by incomplete, inconsistent reporting of product information. The Pharmaceutical Product Identifier (PhPID), representing products by substance, strength, and dose form, may support more granular analyses. Objective: To explore the use of PhPID-like dose form information for site-specific disproportionality analysis in dexamethasone. Methods: We evaluated VigiBase reports (January 1, 2001 - December 31, 2024) for completeness of dose form and route data. We standardized dexamethasone entries to PhPID Level 3 standards, representing substance and administrable dose form. Through disproportionality analysis (Information Component, IC) we compared substance-level and site-specific results. Results: Among 56.4 million suspected/interacting drugs, dose form was reported in 47.7%, route in 69.4%. Among 109,248 dexamethasone entries, 703 dose form and 80 route variations were mapped to 53 and 44 standard codes respectively; about half could be mapped unambiguously. Site-specific analyses revealed biologically plausible patterns not apparent in substance-level analyses. Ocular use showed higher ICs for glaucoma and cataract, while systemic use showed higher IC for psychiatric and endocrine events (e.g., depression, agitation, Cushing's syndrome). IC time-trends suggested that some signals (e.g., cataract with Ocular use) could emerge earlier in site-specific analyses. Conclusion: More granular product information, aligned with PhPID, may improve signal detection and characterization of site-specific safety issues. These findings support granular identifiers in pharmacovigilance while highlighting the need for better capture and standardization of dose form and route of administration data.

Purpose In deprescribing studies, a prescription-free gap is typically used to determine if patients discontinued their treatment. An appropriate gap depends on the typical time between prescriptions during continued use. This work aims to characterise the interval between prescriptions of chronic drugs using different methods for a cohort of older people in primary care in Ireland. Methods The empirical prescription interval was analysed for 38,154 patients for the twenty most common drug classes and the association between covariates and the interval was analysed using a multi-level model. Estimates were also compared to those obtained from the parametric waiting time distribution (pWTD) approach. Results Available covariates had consistent relationships with prescription intervals across drug classes. For example, each additional prescription issue was associated with an increase in the interval by 5.0 (NSAIDs) to 19.7 days ("Other antidepressants"). Full public health cover was associated with a -29.0 day (inhaled adrenergics) to -11.0 day (opioids) change relative to partial cover, while other/private cover had a -17.9 day (benzodiazepines and associated drugs) to -7.1 day (SSRI and SNRIs) change relative to partial cover. The pWTD also produced consistent estimates of the population interval for most drugs. Conclusions The interval varied substantially within drug classes, due to a mixture of patient, practice and unmodelled factors. Variation between practices was effectively explained, with residual variation between patients and within patients. The pWTD approach is useful for describing complex distributions of intervals, and may be more appropriate for inferring a gap than summarising truncated data.

Background. Polypharmacy is an important source of phenoconversion caused by drug interactions potentially modulated by genetic variability. Aims. To develop a linear phenoconversion model for TDM data and provide quantitative estimates of drug-drug-gene interactions (DDGIs) in the pharmacogenetic phenotype groups of CYP2C19. Methods. Escitalopram TDM data in a large real-world sample (n=2,852) was analysed for phenoconversion of CYP2C19 activity. Co-medication was identified by reprocessing high-resolution mass-spectra (Orbitrap). We developed a statistical model to identify inhibition from co-medication in the CYP2C19 and in alternative elimination pathways. We extended the model to estimate the inhibition ensuing from individual co-medications, using a single model for all data to account for multiple co-medications and confounders simultaneously. A Bayesian approach allowed us to stabilize the fit and provide well-calibrated credibility intervals. Results. Reprocessing of TDM analyses identified 17 co-medications, which were shown to phenoconvert CYP2C19 activity proportionally to the activity in non-medicated phenotypes. Phenoconversion decreased the original CYP2C19 activity by about one third for a co-medication that corresponded to a 100% substrate of CYP2C19. The extent of CYP2C19 phenoconversion correlated strongly with the fractional contribution of CYP2C19 to the metabolism of the specific co-medication reported in the pharmacogenetic literature (R2=0.55) so long as the mechanism was competitive inhibition. Conclusion. We provide the statistical methodology to estimate phenoconversion from co-medication in TDM data and combine TDM and pharmacogenetic datasets in future studies aiming at establishing quantitative models of DDGIs.

Study objective. Some acetaminophen-overdose patients develop hepatotoxicity despite acetylcysteine treatment. Established tools struggle to prospectively identify this cohort. We developed a model using only routine admission biomarkers to identify acetylcysteine-treated patients at highest risk, and compared it with the current benchmark, the alanine aminotransferase x acetaminophen product (ALTxAPAP). Methods. Retrospective cohort of all acetaminophen overdose admissions (ICD-10 T39.1) to three UK hospitals (2008-2024) with alanine aminotransferase (ALT) >1000U/L at admission. We fitted elastic-net logistic models stratified by presentation ALT. The outcome was peak ALT >1,000U/L. Performance was assessed on a 25% held-out test set and benchmarked against ALTxAPAP. Results. Of 4,705 admissions, 119 (2.5%) developed hepatotoxicity. The model used seven routine blood tests, four per stratum: acetaminophen, sodium, potassium and lymphocyte count where presentation ALT was <50U/L; ALT, bilirubin, alkaline phosphatase and lymphocyte count where it was 51-1,000U/L. In the test set (n=1,175) it achieved an area under the curve of 0.93 (95% CI 0.89-0.97) versus 0.82 (0.72-0.91) for ALTxAPAP (paired difference 0.11; 95% CI 0.01-0.22; p=0.03), with higher specificity and a higher positive likelihood ratio at every matched sensitivity. Matched to current ALTxAPAP >1,500 practice (sensitivity 89.7%), specificity was 82.5% versus 62.6% and the positive likelihood ratio 5.1 versus 2.4, more than halving false-positive escalations (171 versus 365 per 1,000 patients). Conclusion. A stratified model using only routine admission biomarkers identifies acetylcysteine-treated patients at highest residual hepatotoxicity risk, outperforming the ALTxAPAP rule across decision thresholds, supporting selection for intensified therapy.

Background: Sphingosine 1-phosphate receptor (S1PR) modulators can cause transient, dose-related negative chronotropic effects. Mocravimod is an oral S1PR modulator that is developed as a maintenance therapy in allogenic haematopoietic cell transplantation (allo-HCT). This phase I study evaluated whether two dose-titration regimens attenuate early bradycardia when initiating mocravimod while preserving pharmacokinetic (PK) and pharmacodynamic (PD) activity. Patients and methods: In this randomized, double-blind, placebo-controlled, parallel-group study, healthy adults received once-daily oral mocravimod using either dose titration (DT) regimen DT1 (0.3-2.0 mg with 4-day stepwise escalation) or regimen DT2 (0.5 mg to Day 14, 1.2 mg Days 15-18, then 2 mg), a fixed 2 mg regimen, or placebo for 21 days. The primary endpoint was the number of bradycardia episodes on treatment initiation and dose-escalation days derived from 24-hour Holter monitoring; PK of mocravimod and mocravimod-phosphate (whole blood) and PD effects (absolute lymphocyte count [ALC]) were assessed. Results: Fifty-six participants were randomized and 53 completed the study. Both titration regimens resulted in fewer bradycardia episodes than fixed initiation at 2 mg during the first week of treatment. Differences between titration and fixed dosing were no longer evident after Day 9, consistent with tolerance development. PK profiles were consistent with prior phase I data. By Day 21, DT1 achieved exposures close to the fixed 2 mg regimen, whereas DT2 yielded lower exposures, reflecting slower escalation. Peripheral lymphopenia developed in all active treatment groups and was comparable between regimens by Day 21, returning toward baseline by study end. Safety was similar between titration regimens and placebo, with similar distribution and incidence of adverse events. No serious adverse events occurred. Conclusion: Two practical titration regimens mitigated the early negative chronotropic effect observed with fixed-dose initiation of mocravimod at 2 mg once daily. Importantly, titration preserved the expected PK and PD profile, supporting dose escalation as an effective initiation strategy to improve early cardiac tolerability.

Introduction: Adverse drug withdrawal events (ADWEs) are a key safety concern with deprescribing but are infrequently reported in trials. Although pharmacovigilance systems have advanced our understanding of medication-related harms, it is unclear how extensively these systems have been used for ADWEs. Objectives: To examine the reporting patterns of ADWEs for all drugs recorded in United States and European pharmacovigilance databases between 2004 and 2023. Methods: A retrospective study was conducted using two pharmacovigilance databases, the publicly available FDA-FAERS dataset and EMA-EV Level 2A (individual-level) dataset. ADWE cases were identified using relevant MedDRA preferred terms. Data on patient characteristics, reporter type, drugs, indication, ADWE outcomes, dechallenge/rechallenge, seriousness criteria, time to onset, duration, and causality were summarised. Results: A total of 158,505 ADWE reports were analysed (FDA-FAERS: 145,514; EMA-EV: 12,987), with mean ages of 46.1 (FDA; 55.3% female) and 45.5 years (EMA; 57.1% female). The frequently reported drug classes were opioids (FDA: oxycodone, 29.8%; EMA: buprenorphine, 19%), antidepressants (FDA: duloxetine, 32%; EMA: venlafaxine, 25.9%) and gabapentinoids (FDA: pregabalin, 6.7%; EMA: pregabalin, 6.0%). The most common adverse outcomes were other serious medical conditions (FDA=63.9%; EMA=46.0%), hospitalisation (FDA=15.9%; EMA=28.3%), and disability (FDA=13.3%; EMA=6.2%) and these outcomes varied significantly based on sex and age group (p<0.05). Conclusions: This study provides novel evidence of reporting patterns and characteristics of ADWEs across drugs in pharmacovigilance data. These findings emphasise that adverse drug reaction reporting systems need to accommodate ADWEs (i.e., clarity on terminologies, dechallenge/rechallenge, causality assessment) to effectively capture ADWE-related data to support evidence-based deprescribing practices for better patient safety

Introduction: Pediatric nicotine exposures remain an important and preventable public health issue, particularly with the rapid expansion of electronic nicotine delivery systems. This study compared demographic characteristics, exposure circumstances, and clinical outcomes between pediatric cases involving nicotine devices and bottled liquids reported to U.S. poison centers. Method: This retrospective cohort study analyzed National Poison Data System cases from 2011-2022 involving children aged less than 6 years exposed to nicotine devices or bottled liquids. Analyses were limited to cases with definitive medical outcomes. The primary outcome was defined as a moderate or major clinical effect or death. Odds ratios with 95% confidence intervals were calculated, with a secondary analysis restricted to route-concordant exposures. Results: The final cohort included 15,497 cases: 10,168 device exposures and 5,329 liquid exposures. Demographic characteristics were similar between groups. Device exposures more frequently involved inhalation, while ingestion predominated overall. Clinical effects were typically mild and transient, with vomiting and coughing most commonly reported. The primary outcome occurred in 1.9% of device cases and 2.0% of liquid cases (OR = 1.05; 95% CI 0.82-1.34). A secondary analysis restricted to inhalation-only device exposures and ingestion-only liquid exposures similarly found no significant difference in clinically important outcomes (OR = 1.38; 95% CI 0.92-2.12). Two deaths occurred, one in each group. Conclusion: These findings suggest that, despite differences in formulation and route of exposure, nicotine devices and bottled liquids produce broadly similar clinical toxicity profiles in young children. Prevention strategies should address all household nicotine products rather than focusing on specific delivery systems.

Background: Adverse drug withdrawal events (ADWEs) are a key safety concern during deprescribing but remain poorly explored in pharmacovigilance systems. Objectives: To identify and compare ADWE signals across drug classes, different drugs within drug classes, and across patient characteristics, countries, and over time. Methods: A case/non-case disproportionality analysis was conducted in FDA-FAERS and EMA-EudraVigilance pharmacovigilance databases, with stratification by age (adults: 18-64, older adults: [&ge;]65), sex (male/female), reporting time (2004-2023 in 5-year intervals), and country (for EMA data). Disproportionality analysis (quantitative signal detection) was used to detect signals between ADWEs and drugs using the proportional reporting rate (PRR[&ge;]2), reporting odds ratio (ROR>1), and information component (IC>0) with case count [&ge;]5. Results: Overall, 158,501 reports (FDA-FAERS 145,514; EMA-EudraVigilance 12,987) included drug-event pairs related to ADWEs. In FDA-FAERS, clobetasone (IC=5.58; PRR=79.18; ROR=176.90) showed the strongest ADWE signals, followed by hydromorphone (4.85; 29.94; 37.37), hydrocodone, and paroxetine. In EMA-EudraVigilance, ethyl loflazepate (IC=6.01; PRR=119.80; ROR=197.53), clobetasone (5.39; 102.73; 155.10), veralipride, and levomethadone had the strongest signals. Most drugs maintained positive ADWE signals in analysis stratified into adults and older adults. However, among the top 10 drugs (based on highest IC values), buprenorphine/naloxone, desvenlafaxine, and baclofen in FDA-FAERS (ICs 4.95-6.05) showed stronger signals in older adults. A sex-based difference was observed, with paroxetine, venlafaxine, and buprenorphine/naloxone showing a stronger positive signal in females in both databases, whereas several opioids had stronger signals in males versus females across both databases. Conclusion: This study suggests ADWE signals for some medications differ by age and sex, potentially indicating different risks for withdrawal effects.

Background Statins and ezetimibe are the preferred lipid-lowering therapies (LLTs) for children with heterozygous familial hypercholesterolaemia (HeFH). Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are newer add-on therapies for individuals not achieving low-density lipoprotein-cholesterol (LDL-C) targets. We evaluated the efficacy and safety of PCSK9i in children aged <18 years with HeFH. Methods Systematic review and pairwise meta-analyses of randomised-controlled trials (RCTs) of evolocumab, alirocumab and inclisiran. Comprehensive bibliographic searches were conducted in February 2026. Risk of bias was assessed with Cochrane RoB 2. Results Of 2798 unique records screened, three RCTs were included (n=451, mean age 13 years, follow-up 24 to 47 weeks). Each trial evaluated either evolocumab, alirocumab or inclisiran against placebo as add-on to baseline LLT. Participants had elevated LDL-C (>3.4 mmol/L [130 mg/dL]) despite stable LLT. Overall risk of bias was low. PCSK9i reduced LDL-C by an average of 35.44% (95% CI -41.74 to -29.14, I2=50.8%) and by 1.63 mmol/L [62.93 mg/dL] (95% CI -1.86 to -1.39, I2=18.6%) compared with placebo. There was no evidence of differences between PCSK9i and placebo in tolerability, growth and maturation, and overall incidence of adverse events. Conclusions PCSK9i add-on therapy leads to substantial reductions in LDL-C in paediatric patients with HeFH failing to achieve LDL-C targets with standard LLT. While the findings of this review support the use of PCSK9i in a subset of children and young people with HeFH, limited trial numbers and short follow-up periods underscore the need for future high-quality studies evaluating long-term safety, effectiveness and cost-effectiveness.

Background and aims Over the past decade, there has been increased lifetime use of illicit and medical cannabis, underscoring the need to examine public health impacts. This included reports of increased cannabis-related psychosis. In this context, this study aimed to determine all cannabis-related hospital admissions over a ten-year period to characterise poisonings and mental health harms. Design This is a retrospective observational study of the Victorian Admitted Episodes Dataset (VAED) records, which include all hospital admissions in the state of Victoria and are supplied by the Victorian Department of Health. Setting Victoria, Australia. Cases Hospital records for poisoning (T40.7) and mental health and behavioural disorders (F12.0-F12.9) related to use of cannabis for the period July 2013 to June 2023 were selected for this study. Measurements Crude and age-standardised rates per 100,000 population are reported. Net percentage change over the ten-year study window was estimated using generalised linear models with a log-population offset, contrasting the final year (2022/23) against the baseline (2013/14). Findings There were 39,565 cannabis-related admissions in the ten-year period, including 7263 admissions where cannabis-related harm was the principal diagnosis. The age-standardised rate per 100,000 population was 63.6 for all cannabis-related harm admissions and 11.7 for principal diagnosis cases. The peak annual rate for all cannabis-related harm was observed in 2020/2021 (77.3 per 100,000). There was a 49.0% (p<0.0001) increase in the rate of hospital admissions with a cannabis-related principal diagnosis, when comparing 2022/23 with baseline (2013/14). Overall, harmful use (F12.1) was the most common cannabis-related mental and behavioural disorder. Psychotic disorder (F12.5) was the most common diagnosis (45.3%; n=2,909/6,421). When considering principal diagnosis only, the rates were highest in males aged 15-24 years (36.9/100,000), followed by females in the same age group (20.5/100,000). While most principal diagnosis cases involved males, a greater percentage change between the first and last years of the study period was observed for females (+75.1%, p<0.0001) compared with males (+34.6%, p=0.003). Conclusions A 49% increase in the rate of cannabis-related hospital admissions, particularly mental and behavioural disorders due to use of cannabinoids, has occurred over the past decade. These trends are non-linear, rates in the last two years were lower than the peak in 2020/2021.

Objectives: To compare real-world cardiovascular outcomes and safety events in patients with resistant hypertension following initiation of transdermal clonidine (TC) or spironolactone. Methods: A retrospective analysis was performed using Merative MarketScan(R) Databases in the USA to identify cohorts with resistant hypertension initiating TC or spironolactone as a fourth-line agent between January 2012 and September 2024. Major Adverse Cardiovascular Events (MACE) and safety events were assessed during variable follow-up periods. Inverse probability of treatment weighting (IPTW) was applied to adjust for differences in baseline characteristics. Cox proportional hazard models were used to adjust for post-index beta-blocker utilization as a time-varying covariate for MACE outcomes. Results: The analysis included 3,113 patients in the TC cohort and 30,640 in the spironolactone cohort. After IPTW, baseline characteristics were well balanced between cohorts (standardized mean differences <0.10; mean age 60 years, 54% male). Mean follow-up was 7.1 and 10.5 months for the TC and spironolactone cohorts, respectively. After IPTW no differences in MACE outcomes were observed between the two cohorts (weighted rate ratio 1.27 [0.79-2.06]). Results were consistent after adjusting for post-index beta-blocker use. The risk of hyperkalemia was significantly lower in the TC cohort (weighted rate ratio, 0.48 [0.33-0.70]. Conclusions: In this real-world analysis, patients with resistant hypertension treated with TC have similar risk for MACE outcomes as with spironolactone, but with significantly lower risk of hyperkalemia. Thus, in patients with resistant hypertension TC appears to provide similar cardiovascular protection, with a more favorable safety profile.

INTRODUCTION: Drug-related-problems (DRPs) are encountered daily in prescription medicines at the community pharmacy but they are neither documented nor evaluated systematically. Population ageing in Greece is expected to increase polypharmacy and consequently DRPs, thus deteriorating patients` health and pressuring the already underfunded health system. Community pharmacists are ideally placed to review patients` medicines and in collaboration with physicians resolve identified issues. OBJECTIVES: The primary outcomes of the study were to define the number and nature of DRPs identified in prescription medicines at an urban community pharmacy in Greece. Secondary outcomes included the assessment of severity of errors and, for the evaluation part of the project, planned interventions to address them. METHODS: Our study was divided into two parts: the main part which included the evaluation of the current service and a following small-scale improvement project. For the first aspect, all prescription medicines dispensed from the pharmacy within one month were analyzed, using primary data extracted directly from pharmacy prescription and medication records. Medication characteristics as indicated in prescriptions (name of drug, dosage, formulation, dosing interval) and patients` medication records were utilized as sources of information. The identification of DRPs was based mainly on explicit criteria and reliable sources. Potential DRPs were classified following the Pharmaceutical Care Network Europe (PCNE) classification system (2019) while their severity was assessed and documented according to a tool developed by Abdel-Qader et al. (2010). A comprehensive approach of medication review as defined in `Polypharmacy Guidance: Realistic Prescribing` (Scottish Government Polypharmacy Model of Care Group, 2018) and patient interviews as an additional source was followed for the 4 selected patients in the second part of the study. RESULTS/DISCUSSION: In 635 prescriptions containing 1464 medicines we identified 364 DRPs in 529 different patients. The most common problem was related with a possible adverse drug event (P2.1, 62.1%) while 62% of the causes that led to problems belonged to inappropriate combination of drugs (C1.4), inappropriate drug (C1.2), drug dose too high (C3.2) and duration of treatment too long (C4.2). Most DRPs were characterized as significant (n=202, 55.5%) and minor (n=110, 30.2%) while the intervention `drug changed to` (I3.1, 25.8%) was the most frequent among the planned interventions. In the improvement project, 39 DRPs were identified in the 4 enrolled patients, including errors associated with potential inappropriate omissions and absence of monitoring not discovered in the first part of the study. CONCLUSION: We quantified the potential DRPs encountered in a community pharmacy and discovered that for every 4 medicines dispensed 1 potential DRP was identified. Even if all errors will not result in harm, they will create additional work and possibly lead to prescribing cascade. Additional sources of information, like the patient interviews we incorporated in the improvement project, are expected to increase the number and consistency of findings. Finally, the value of community pharmacists as a vital component of primary care was pointed out.

Background. Compounded tirzepatide is prescribed at scale as a cheaper substitute for branded Mounjaro and Zepbound, yet the cost case is almost always built by setting one compounded price against one branded list price. That framing ignores the question that actually decides the answer: cheaper than which branded price the patient can reach. Branded tirzepatide is now sold at sharply different tiers, namely insurance copay (often $25-$150/month), LillyDirect Self Pay ($299-$449/month), and retail cash price ($1,000-$1,200/month). Whether compounded saves money turns entirely on which of these a given patient faces. A second open question is whether the two formulations even produce comparable effectiveness, since observed differences may reflect selection on insurance, baseline characteristics, and adherence rather than the drug. Methods. We conducted a retrospective cohort study of tirzepatide users in the Mochi Health telehealth program, classified by formulation from their refills as branded-only (Mounjaro/Zepbound; 6,238), compounded-only (71,683), or switchers (4,996); switchers were excluded from the formulation contrast. Among single-formulation patients with a documented six-month weight observation, the analytic cohort was 7,271 (869 branded, 6,402 compounded). The primary outcome was six-month percent body weight loss; the secondary outcome was >=10% response. We used 1:1 nearest-neighbor propensity-score matching (0.25 SD caliper) on baseline covariates only - age, sex, baseline BMI, baseline weight, comorbid diabetes, hypertension, dyslipidemia, prior bariatric surgery, and self-reported insurance coverage - deliberately excluding post-treatment variables such as adherence and time in program, which are mediators of the formulation effect. We pre-specified an equivalence margin of +/-2 percentage points on mean loss and tested equivalence with two one-sided tests (TOST). A directed acyclic graph (DAG) makes the identifying assumptions explicit; metformin use could not be reliably ascertained and is treated as an unmeasured confounder. The cost comparison reports the savings or premium of compounded versus branded under five branded price scenarios: retail list, LillyDirect Self Pay (two dose tiers), and insurance copay (typical and low end). It is a cost comparison (cost-minimization under demonstrated similar effectiveness), not a formal cost-effectiveness analysis: we computed no ICER, QALY, or discounting. Results. Branded and compounded patients had similar outcomes even before adjustment (mean loss 11.7% vs 11.5%; >=10% response 60.9% vs 58.8%). The largest baseline difference between the groups was insurance coverage (branded patients far more likely insured; standardized mean difference 0.67), which matching balanced to 0.01. After 1:1 matching (718 pairs, all |SMD| < 0.04), mean loss was 11.4% vs 11.4% (difference +0.08 pp, 95% CI -0.70 to +0.80) and >=10% response 59.3% vs 57.2% (difference +2.1 pp, 95% CI -3.1 to +7.1). The two formulations were statistically equivalent within the pre-specified +/-2 pp margin (TOST p < 0.001). Cost depends on the branded scenario: compounded saves $6,000 over six months versus retail list price, $1,494 versus LillyDirect maintenance-dose (5-15 mg) Self Pay, and $594 over a low-dose (2.5 mg) LillyDirect prescription, while it costs $300 more than branded under a typical insurance copay ($150/month) and is more expensive still at lower copays (savings turn negative below $200/month). Conclusions. Branded and compounded tirzepatide were statistically equivalent in six-month effectiveness within a pre-specified +/-2 pp margin, so the choice between them is essentially a cost decision - and that cost advantage is real but conditional on the branded price the patient can access. It is large against retail list price and shrinks to zero or reverses against LillyDirect Self Pay or a low insurance copay. Whether compounded is the lower-cost choice for an individual patient is, therefore, a question about which price tier that patient faces.

Background: Dietary supplements (DS) are extensively used in Pakistan, frequently in conjunction with prescription medicines. Pharmacists are well positioned for patient counsesling due to their accessibility. However, their ability to provide evidence-based counseling remains uncertain due to their varying knowledge and training, especially in low- and middle-income countries (LMICs), including Pakistan. The study assessed pharmacists' knowledge, attitudes, and practices (KAP) regarding DS counseling and identified gaps requiring intervention. Methods: A cross-sectional study was conducted among 256 registered pharmacists in Lahore, Pakistan. Data were collected using a validated, self-administered questionnaire assessing knowledge, attitudes, and counseling practices concerning dietary supplements over a period of six months i.e., July to December 2025. Statistical analyses were performed using SPSS version 27. A p-value of < 0.05 was considered statistically significant. Results: Mean age was 31.0 {+/-} 6.2 years, with male predominance (56.3%), Doctor of Pharmacy degree (75.0%), community pharmacy practice (62.5%), and 1-5 years of experience (48.4%). Mean knowledge score was 6.18 {+/-} 1.71, with most (76.6%) exhibiting moderate knowledge. Mean attitude score was 7.01 {+/-} 1.94, with 91.4% demonstrating positive attitudes. Mean practice score was 7.91 {+/-} 2.93, with 68% exhibiting good counseling practices. Knowledge scores were significantly higher among female pharmacists (6.96 {+/-} 1.52 vs. 5.57 {+/-} 1.61, p=0.001), urban residents (6.39 {+/-} 1.61 vs. 4.37 {+/-} 1.30, p<0.001), and clinical pharmacists (7.10 {+/-} 1.68, p=0.001). Conclusion: Pharmacists practicing in Lahore, Pakistan demonstrated positive attitudes but moderate knowledge and inconsistent counseling practices. Key gaps were identified in drug-supplement interaction knowledge and counseling practices. These findings underscore the need for organized education, continued training, and regulatory supervision to improve counseling practices of dietary supplements.

Background: Retrieval of adverse event reports based on coded drug-event co-occurrence enables large-scale pharmacovigilance analyses, but yields candidate reports rather than validated cases, risking misinterpretation if used alone. Aim: To develop and apply a framework for identification and characterization of clinically meaningful case series in pharmacovigilance. Methods: We conducted two case studies. The first developed and refined the framework in an information-rich setting, focusing on drug-induced impulsivity across selected drugs; the second tested its applicability in a more routine, information-poor setting, focusing on drug-induced suicidality. Results: In Case 1, non-relevant reports were frequent for drugs with uncertain evidence and negative controls ({approx}20-40%) compared to drugs with established causal roles (4%). The emerging framework assessed relevance based on exposure, event, drug-event relationship, and population. For suspected adverse drug reactions, relevant reports were further characterized by reporter suspicion and evidentiary qualifiers supporting or refuting causality; higher suspicion was associated with more supportive qualifiers. Applied to Case 2, the framework ruled out 69% of reports as non-relevant but highlighted substantial non-assessability (17%). Conclusions: In pharmacovigilance, retrieval is not equivalent to case identification. Relevance is question-specific and shaped by how reports are captured, processed, and retrieved. This can be especially critical for emerging or bias-prone safety questions. Transparent and reproducible case definition and adjudication are essential for interpretable analyses.

Congenital adrenal hyperplasia (CAH) is a rare inherited disorder requiring lifelong hormone replacement therapy. Excessive hormone replacement poses a significant risk for long-term complications, such as hypertension; however, quantitative approaches for optimizing dosing remain underdeveloped. This study aimed to identify factors associated with hypertension in patients with CAH and to develop a predictive model to support longitudinal fludrocortisone dose adjustment in pediatric patients who were already receiving mineralocorticoid replacement. We first employed generalized linear mixed models (GLMM) to evaluate the relationships among therapeutic agents, biochemical markers, and hypertension. Our results indicated a significant positive association between the dose of fludrocortisone (FC) and diastolic hypertension, whereas no such association was observed for the dose of hydrocortisone (HC). Using expert curated data, we subsequently constructed multiple predictive models, including CatBoost, XGBoost, and LightGBM, to enable individualized adjustment of FC dosage. All models were evaluated on an independent test set, with CatBoost, XGBoost, and LightGBM demonstrating comparably strong performance (R^2: 0.75 to 0.77). Subgroup analyses revealed that predictive accuracy was highest in children aged 0 to 2 years, where the top-performing model achieved a mean ideal prediction rate of 59.6%. This study not only confirms the significant link between FC dosing and hypertension in CAH patients but also provides a machine learning based decision support tool to assist individualized longitudinal dose adjustment. The model shows promise as a clinical decision-support instrument to facilitate personalized and precise management of CAH therapy.

Background: This study aimed to evaluate real-world adverse event (AE) signals of EV to provide evidence-based guidance for its safe clinical application. Methods: Data from the FDA Adverse Event Reporting System (FAERS) database from the period of 2019 Q1-2025 Q3 were analyzed. Disproportionality analysis algorithms, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM), were utilized to mine safety signals.The time to onset (TTO) was evaluated using the Weibull distribution model. Results: Among 11,697,906 reports, 4,177 EV-treated patients experienced 14,511 AEs. The most common System Organ Classes (SOCs) were skin and subcutaneous tissue disorders (18.23%), general disorders and administration site conditions (13.17%).Multi-algorithm consensus identified 179 positive signals. Alongside known toxicities (rash, peripheral neuropathy, hyperglycemia), potential new signals emerged, including dysgeusia, atypical skin lesions, and myelosuppression. Median TTO was 14 days, with the Weibull {beta} of 0.736, confirming an "early failure" profile. Subgroup analysis revealed toxicity heterogeneity: patients aged [&ge;]65 and females exhibited stronger signals for fatal severe cutaneous adverse reactions, while patients aged < 65 and males showed higher susceptibility to neurological and metabolic toxicities. Conclusions: The real-world safety profile of EV confirms known toxicities, reveals new risks (e.g., dysgeusia), and shows toxicity concentrated in the first treatment cycle. Clinical practice requires proactive monitoring during the first two weeks using demographic-specific strategies: vigilance for fatal skin toxicity in elderly and female patients, and close follow-up of neurological and metabolic indicators in younger and male populations.

Background: Endocrine-disrupting chemicals (EDCs) in consumer products are ubiquitously detected in human biospecimens, yet most epidemiological studies examine single chemicals rather than real-world co-exposures. We evaluated associations between a mixture of seven urinary chemical biomarkers and systemic inflammation. Methods: Survey-weighted log-log regression models adjusted for age, sex, race/ethnicity, poverty-income ratio, and survey cycle were conducted with Benjamini-Hochberg FDR correction (primary analysis, N=4,864). A sensitivity analysis additionally adjusted for body mass index and smoking status (N=4,494). Results: In the primary analysis, 5 of 7 chemicals showed significant associations after FDR correction: ethylparaben ({beta} = -0.056, FDR P < .001), propylparaben ({beta} = -0.026, FDR P = .007), bisphenol A ({beta} = +0.052, FDR P = .005), monoethyl phthalate ({beta} = +0.043, FDR P = .002), and monocyclohexyl phthalate ({beta} = +0.215, FDR P = .007). The WQS mixture index was significantly associated with CRP ({beta} = +0.056, 95% CI [0.031, 0.081], P < .001), with monocyclohexyl phthalate carrying the largest mixture weight (0.342). In the BMI- and smoking-adjusted sensitivity analysis, associations attenuated to null for all chemicals, though MCP preserved direction ({beta} = +0.129) and the WQS mixture direction was maintained ({beta} = +0.018). Two multiple imputation sensitivity analyses confirmed that monocyclohexyl phthalate was the only chemical to maintain a positive direction across all four analytical specifications (primary complete-case, BMI-adjusted complete-case, primary-aligned imputation, and BMI-adjusted imputation), reaching statistical significance in three of four specifications and providing convergent evidence of a robust MCP-inflammation association. Conclusions: The chemical mixture showed a significant collective association with systemic inflammation, consistent with a cumulative pro-inflammatory burden from co-exposure to multiple consumer product chemicals. These findings suggest that regulatory approaches should shift from single-chemical to mixture-based risk assessment frameworks for consumer product safety.

Background Despite available lipid-lowering therapies (LLT), many patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets. This gap persists across clinically relevant subgroups. Bempedoic acid has demonstrated effective LDL-C lowering with a favorable safety profile in the CLEAR Taiwan study; however, its effects across subgroups in Asian populations remains limited. Methods The phase IV CLEAR Taiwan study (NCT06925100) enrolled patients with inadequately controlled hypercholesterolemia who received bempedoic acid for 12 weeks in addition to background LLT. This analysis evaluated changes in lipid parameters, high-sensitivity C-reactive protein (hsCRP), and safety outcomes in clinically relevant subgroups, including cardiovascular risk, diabetes, age, statin tolerance, and sex. Results A total of 180 patients were included. Bempedoic acid achieved significant LDL-C reductions in all subgroups. Numerically greater LDL-C reductions were observed in primary prevention, statin-intolerant, younger (< 65 years), and female patients, while comparable reductions were observed across diabetes status. Reductions in non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B were consistent with LDL-C findings. Significant decreases in hsCRP were observed in all subgroups, with numerically greater reductions in patients aged < 65 years and those without diabetes. Bempedoic acid was well tolerated, with a low incidence of adverse events and no new safety signals identified. Changes in liver enzymes, renal function, and uric acid were minimal within subgroups. Conclusion Subgroup analyses from the CLEAR Taiwan study demonstrate consistent efficacy and safety of bempedoic acid across clinically relevant subgroups and support its use as a flexible option to address residual gaps in lipid management.

Background Proton pump inhibitors (PPIs) have been proposed as a risk factor for initial and recurrent Clostridioides difficile infection (CDI) based on observational data. Whether desprescribing PPIs reduces the odds of incident CDI is unknown. Methods This was a secondary analysis of the cluster randomized MedSafer clinical trial dataset, in which hospitalized older adults taking five or more medications were randomized to usual care (a medication review) or electronic deprescribing decision support prior to hospital discharge. For this substudy, all patients were included regardless of trial assignment and were categorized according to their PPI use at hospitalization and discharge. The 30-day occurrence of CDI was compared as a function of PPI use using a Bayesian mixed-effect logistic regression adjusted for prespecified confounders. Results 4990 patients were included in the analysis, including 405 (8.1%) patients who were deprescribed their home PPI and 325 (6.5%) new PPI users. 30-day CDI occurred in 32 (0.6%) patients. PPI deprescription was associated with a 99.1% probability of increased odds of CDI (adjusted odds ratio[aOR]=3.66, 95%Credible interval[95%CrI]=1.25-10.11). New PPI use, however, was not associated with a probable increase in CDI (aOR=1.14, 95%CrI=0.20-4.67). Conclusion Unexpectedly, PPI deprescription was associated with a higher odds of CDI. This challenges the practice of deprescribing unnecessary PPIs in hospitalized patients for CDI prevention. However, it is possible this finding is artefactual due to confounding by indication. Further mechanistic and confirmatory studies are needed.